CG From the
-
Treating Heart Disease With Gene Therapy
1/19/2024
Tenaya Therapeutics' TN-201 is a clinical-stage gene therapy aimed at treating the leading cause of death in the world — heart disease. Tenaya CEO, Faraz Ali, explains the company's journey in developing TN-201, as well as some lessons he's learned throughout his career, and what he's most excited to see in the field heading into 2024.
-
ARM’s State Of The Industry Briefing At JPM 2024
1/9/2024
Here's a recap of ARM’s CEO Tim Hunt's 2024 State of the Industry Briefing presentation at JPM 2024.
-
Cell & Gene: The Podcast Episodes From ARM’s 2023 MOTM
12/21/2023
All three episodes of Cell & Gene: The Podcast recorded at ARM's 2023 Meeting on the Mesa have now aired. Here's a look at my guests and the important CGT topics we discussed.
-
iCell, Coeptis On FDA’s Investigation Of CAR T Immunotherapies
12/18/2023
Last month, the FDA stated it was investigating serious risks of T-cell malignancies in patients following treatment with a chimeric antigen receptor (CAR) T-cell therapies. I met up with Yupo Ma M.D., Ph.D. Chief Scientific Officer at iCell Gene Therapeutics, and Dave Mehalick, CEO and Colleen Delaney, M.D., Chief Scientific and Medical Officer at Coeptis Therapeutics to get their reaction to the FDA’s investigation.
-
Moving Beyond AAV: The Next Generation Of Vectors In CGT
12/11/2023
We catch up with Dr. Konstantin Konstantinov, CTO at Ring Therapeutics, and Ryan Crisman, Ph.D., cofounder and CTO at Umoja Biopharma, to get their thoughts on the future of new anellovirus vectors and existing lentiviral vector technology for in vivo gene delivery respectively.
-
Preparing Your CAR-T Therapy For Phase 2 Trials
12/6/2023
AffyImmune CEO, Matt Britz, talks about what’s next for the company as it prepares its lead CAR-T candidate for Phase 2 trials — from clinical strategy to selecting a CDMO and the headache of tech transfers.
-
Video Clips From Cell & Gene Live: Optimizing Your Cold Chain For Cell Therapies
11/30/2023
For your convenience, we’ve broken down our Cell & Gene Live, Optimizing Your Cold Chain for Cell Therapies, into bite-size video clips by topic.
-
A Sneak Peek At Providence Therapeutics On Cell & Gene: The Podcast
11/29/2023
On an upcoming episode of Cell & Gene: The Podcast, I talk to Robert Georgantas III, Ph.D., of Providence Therapeutics, about their mRNA vaccine therapies. Here's a preview of our conversation.
-
Vor Bio Shares Progress For Patients with AML
11/17/2023
I talked to Dr. Robert Ang, President and Chief Executive Officer at Vor Bio about the company's VBP101 study for trem-cel in patients with acute myeloid leukemia (AML)
-
The Eye: A Candidate For Modifier Gene Therapy
11/17/2023
Ocugen's Chairman, CEO and Co-founder, Shankar Musunuri ,Ph.D., MBA, provides an update on OCU400 and other ongoing trials, why the eye is a good target for gene therapy, the outlook for retinal gene therapy, and more.